Background
Artemisinin (ART) resistance in malaria parasites is spreading through Southeast Asia and recent reports indicate that resistance has reached Southern Asia [
1‐
3]. As artemisinin-based combination therapy (ACT) is the recommended course of treatment for uncomplicated malaria by the World Health Organization (WHO), the spread of ART resistance raises concerns for the future of malaria treatment [
4]. The ability to track and understand ART resistance will be key in preventing global setbacks in malaria eradication efforts.
Measuring ART resistance is typically done in vivo using patient clearance half-life (PC
1/2), an assay that measures the linear decline of parasitaemia in patients after drug treatment [
5‐
7]. Clinical ART resistance manifests as a delayed clearance of parasites from a patient’s blood following treatment and is defined as a PC
1/2 ≥ 5 h [
7]. While the PC
1/2 provides a method to track ART resistance in the field, it has drawbacks, namely the requirement for patients to meet a strict inclusion criteria and agree to hospitalization to measure the PC
1/2 [
8]. To avoid this costly measure, in vitro measures of ART resistance have been developed. One of the most common in vitro measures of antimalarial drug resistance is the 50% inhibitory concentration (IC
50), which exposes parasites to serial dilutions of drug. However, delayed parasite clearance (as measured by PC
1/2) is not associated with a significant change in ART IC
50 [
8‐
10]. This is because later parasite stages (such as trophozoites and schizonts) are highly susceptible to ART, but early ring-stage ART resistant parasites (0–3 h) are able to survive pulses of ART. Therefore, the ring-stage survival assay (RSA) was developed to distinguish ART resistant parasites in vitro and to have a better correlation with PC
1/2 data than ART IC
50s [
6,
8,
11].
The RSA has been the gold standard for measuring ART resistance in vitro, but it is a multi-step, laborious, and time-consuming assay that requires high volumes of very synchronized parasites. It is essential that the parasites are tightly synchronized in order to assay during the short window (0–3 h) that can differentiate ART resistant parasites from ART sensitive parasites. To do this, both a Percoll gradient and sorbitol are typically used [
8], but several alterations have been attempted previously in other malaria assays to increase the throughput of the assay such as using both sorbitol and magnet columns [
12], using syringe filters to select for merozoites [
13], and using a dual layer Percoll gradient [
14,
15]. Throughput of these various methods is dictated by the number of samples that can be simultaneously synchronized and prepared for processing. Another major bottleneck and source of variability in the final readout of the RSA is counting viable malaria parasites by microscopy [
8,
11,
14]. To increase throughput, flow cytometry has become heavily utilized as an alternative to counting viable parasites by microscopy, removing hours of counting slides and human error [
14,
16]. However, staining of cells for flow cytometry to detect viable parasites is time sensitive and requires samples to be prepared immediately after the 66 h incubation, which can be time consuming and inconvenient [
14].
Despite these advances in the protocol, the RSA is still far from being both high-throughput and highly reflective of PC
1/2. Recently, Mukherjee et al. used the RSA to measure the percent survival of 36 culture-adapted parasites, but only showed a correlation with PC
1/2 data of 0.377, suggesting there is still significant room for improvement (Spearman’s Rho, internal calculations based off of supplemental data) [
17].
Here a modified RSA is presented: the extended recovery ring-stage survival assay (eRRSA). This modified RSA protocol utilizes a simple single layer Percoll synchronization, flow cytometry to determine the stage and parasitaemia for assay setup, a 96-well plate format for the assay, and a SYBR Green-based quantitative PCR (qPCR) method as the final readout. These modifications allow for an increased throughput in vitro experiment that better correlates with PC1/2, allowing for improved segregation of resistant and sensitive parasites, as well as improved sorting of moderately resistant parasites. Further, efficiency improvements in the eRRSA allow for a higher throughput in vitro testing of ART resistance, accelerating our understanding of artemisinin resistance in the laboratory and providing a more accurate method to track the spread of resistance.
Methods
Parasite isolates
To evaluate the eRRSA methods,
P. falciparum isolates with varying
kelch13 mutations and PC
1/2 were chosen. These isolates were derived from cloning by limiting dilution from patient samples. A total of 15 parasite isolates were chosen, 9 of which have
kelch13 mutations (including one C580Y mutant, the most common
kelch13 mutation found in Southeast Asia currently), and a PC
1/2 distribution between 1.67 and 9.24. All 15 parasite isolates were isolated from patients on the Thailand-Myanmar border between 2008 and 2012. 3D7 was used as a control for comparison to the 15 Southeast Asian isolates (Table
1) [
18,
19].
Table 1Parasite isolates used in this study
NHP1333 | N458I | 9.24 | MKT | 2011 |
NHP1455 | R561H | 8.02 | MKT | 2012 |
NHP1337 | C580Y | 7.83 | MKT | 2011 |
NHP4333 | C538V | 7.7 | WPA | 2008 |
NHP4373 | WT | 7.1 | WPA | 2008 |
NHP3035 | M476I | 6.16 | MLA | 2008 |
NHP4078 | A675V | 5.82 | WPA | 2008 |
NHP4201 | WT | 5.65 | WPA | 2008 |
NHP4106 | WT | 5.54 | WPA | 2008 |
NHP4673 | E252Q | 5.34 | WPA | 2010 |
NHP4748 | WT | 2.89 | WPA | 2011 |
NHP4072 | WT | 2.29 | WPA | 2008 |
NHP3032 | K438N | 2.17 | MLA | 2008 |
NHP4302 | WT | 1.98 | WPA | 2008 |
NHP1386 | WT | 1.67 | MKT | 2011 |
Parasite culture
Plasmodium falciparum isolates were cultured using standard methods in human red blood cells (RBC) (Biochemed Services, Winchester, VA and Interstate Blood Bank, Memphis, TN) suspended in complete medium (CM) containing RPMI 1640 with l-glutamine (Gibco, Life Technologies.), 50 mg/L hypoxanthine (Calbiochem, Sigma-Aldrich), 25 mM HEPES (Corning, VWR, 0.5% Albumax II (Gibco, Life Technologies.), 10 mg/L gentamicin (Gibco, Life Technologies) and 0.225% NaHCO3 (Corning, VWR) at 5% haematocrit. Cultures were grown separately in sealed flasks at 37 °C under an atmosphere of 5% CO2/5% O2/90% N2.
Percoll synchronization
Parasites were synchronized using a density gradient method as previously described with slight modifications [
14,
15,
20]. Briefly, 350 μl of packed, infected erythrocytes at high schizogony (> 50% schizonts) was suspended in 2 ml of RPMI. Cultures were layered over a single 70% Percoll (Sigma-Aldrich) layer in 1 × RPMI and 13.3% sorbitol in phosphate buffer saline (PBS) and centrifuged (1561×
g for 10 min, no brake). The top layer of infected late stage schizonts was then removed and washed with 10 ml of RPMI twice. Cultures were then suspended in 2 ml of CM at 2% haematocrit and placed in culture flasks on a shaker in a 37 °C incubator for 4 h to allow for re-invasion.
Flow cytometry
Four hours after Percoll synchronization (unless noted otherwise), samples were measured by flow cytometry as previously described with slight modifications to determine parasitaemia [
14,
16]. Briefly, 80 μl of culture and an RBC control incubated for at least 8 h at 2% haematocrit in CM were stained with SYBR Green I (SYBR) and SYTO 61 (SYTO) and measured on a guava easyCyte HT (Luminex Co.). Analysis was performed with guavaSoft version 3.3 (Luminex Co.). 50,000 events were recorded for both the RBC control and samples to determine relative parasitaemias.
eRRSA setup
Two hours post-cytometric quantitation (or 6 h after Percoll synchronization) samples whose stage composition was > 70% rings as determined by flow cytometry were diluted to 2% haematocrit and 0.5% parasitaemia (unless otherwise noted), and 200 μl of culture was aliquoted into 6 wells of a flat bottom 96-well plate. Each treated and untreated sample had three technical replicates: RBC controls were aliquoted into 2 wells at 2% haematocrit and 200 μl. Three wells of parasites and 1 well of the RBC control were treated with 700 nM dihydroartemisinin (DHA) (Sigma-Aldrich); an additional 3 wells of parasites and 1 well of RBC control was treated with 0.02% dimethyl sulfoxide (DMSO) (ThermoFisher) as untreated controls. Parasites were incubated for 6 h, and then washed three times with 150 μl of RPMI to remove drug. Samples were then suspended in CM and placed back in the incubator. Sixty-six hours after drug removal, 20 μl of sample from each well was collected and frozen for qPCR amplification (72 h sample) without any media changes. Plates were then placed back in the incubator for another 48 h, after which 20 μl of sample was again collected and frozen for qPCR amplification (120 h sample).
qPCR Amplification
Ring-stage samples were quantified at 72 and 120 h post-drug treatment. qPCR was performed using the Phusion Blood Direct PCR kit (ThermoFisher, cat # F547L), supplemented with 1 × SYBR. Three microlitres of a 1:3 culture dilution was used in a 10 μl reaction and amplified using forward and reverse primers of the
pfcrt gene. PCR amplification was measured using the fast mode of the ABI 7900HT, with a 20 s denaturation at 95 °C, followed by 30 cycles of 95 °C for 1 s, 62.3 °C for 30 s, and 65 °C for 15 s (Additional file
1). Cycle threshold (Ct) values were calculated using the ABI SDS 2.4.1. Fold change (2
ΔCt) was calculated by determining the average ΔCt for the three technical replicates for the untreated and treated samples by applying the following equation:
$$Fold \,change = 2^{{\left( {average \,Ct \,of\, treated\, sample - average \,Ct \,of \,untreated \,sample} \right)}}$$
(1)
All statistics were performed and figures generated using GraphPad Prism version 8.2.1.
Discussion
With the gradual spreading of artemisinin resistance throughout Southeast Asia, it is imperative that resistance can be accurately measured both in the field and in the lab. To date, the RSA has been the golden standard for in vitro measurement of artemisinin resistance. In the clinic, PC
1/2 is the standard for in vivo measurement of artemisinin resistance. The PC
1/2 comprises contributions by both the human host and the parasite. Because the RSA is an in vitro measurement of only the parasite component, the RSA cannot perfectly correlate with PC
1/2 [
24‐
27]. Despite this, there is a need for a more accurate, higher throughput in vitro measurement alternative to the current RSA to accelerate understanding of artemisinin resistance. The eRRSA was developed for this purpose and this study shows that it can outperform the RSA in both accuracy and efficiency.
A major bottleneck and source of variability in the RSA is the final readout to determine the ratio of viable parasites in the treated and untreated cultures. RSA uses microscopy or flow cytometry as the final readout, while the eRRSA uses qPCR. When using microscopy to compare viable and nonviable parasites, the presence of the ring-like structure of healthy, viable parasites are compared to the collapsed, nonviable parasites which can be highly subjective and time consuming, as shown by the original RSA paper which required two to three microscopists [
14]. Flow cytometry utilizes the DNA stain SYBR and the mitochondrial stain MitoTracker red to differentiate between viable and nonviable parasites. This eliminates the requirement of microscopists and drastically decreases the labor required to determine percent proliferation of parasites [
14,
16]. However, staining of cells for flow cytometry is time sensitive and must be done immediately following the end of the RSA (at 72 h), which can limit flexibility and lengthens an assay that already demands long hours. qPCR measure viable parasites solely by concentration of genomic material, comparing the efficiency of parasites to proliferate post-artemisinin perturbation. Here, the efficacy of qPCR is demonstrated as a readout for proliferation in a survival assay context. The use of qPCR allows for both smaller sample sizes and a delayed readout, rendering the protocol easier and more precise.
The eRRSA measures the difference in genomic content between treated and untreated malaria parasites at 120 h post perturbation, a full 48 h (or a full life cycle) after the RSA collections. The results demonstrate that by allowing parasites an extra life cycle to recover, the differences between resistant and sensitive parasites are made even more drastic, suggesting the extra lifecycle for recovery helps further differentiate viable and nonviable parasites. With an extra life cycle for recovery from drug treatment, the eRRSA measures recovery of the parasites, rather than the survivability of the parasites after treatment, and provides a more consistent readout compared to other publications (Additional file
5).
The demonstration of the effect of various setup conditions on the final outcome required an optimization of these parameters in the eRRSA. With no sorbitol synchronization required and only one single layer Percoll synchronization to select schizonts, parasites are synchronized easier, quicker, and closer to the ring-stage so that they can be set up in the assay sooner to avoid losing their synchronization. The variability in assay outcome caused by varying the delay between synchronization and treatment is likely due to the short window (0–3 h) that differentiates ART resistant parasites from ART sensitive parasites. The eRRSA assay is set up 6 h post-Percoll, which allows for a high percentage of early ring-stage, tightly synchronized parasites. Using flow cytometry for parasitaemia measurements post-Percoll synchronization allows for rapid and accurate parasitaemia determination and staging for many parasites at once at the setup of the assay, which is an essential factor for the results of both RSA and eRRSA. Starting parasitaemia has a substantial effect on growth throughout the assay; by using a lower starting parasitaemia (0.5%) compared to the in vitro RSA, the eRRSA has a lower volume and parasitaemia requirement while also allowing for more precise measurement of growth with and without drug treatment. Lower culture volume requirements permit the use of 96-well plates, which uses less reagents, time, and space.
The RSA is a multi-step and time-consuming assay. Even with the optimizations of the eRRSA, the 4 h required to wait until schizonts have reinvaded after single layer Percoll synchronization to obtain 0–3 h ring-stage parasites and the 6 h of drug incubation time cannot be avoided. However, by automating aspects of the assay that have a certain run time regardless of how many samples are being assayed (e.g., flow cytometry in a 96-well plate to set-up parasites and qPCR as the final readout), running larger numbers of samples in parallel does not add a significant amount of time to the assay. In addition to automation, decreasing the culture volumes (by using a 96-well plate) and using a quick and tight synchronization method (single layer Percoll) makes it possible for one researcher to set-up 12–15 parasites samples with technical replicates in a ~ 12 h day (Additional file
4).
Finally, it was demonstrated that the eRRSA shows superior correlation with the clinical phenotype PC
1/2. As ART resistance is currently presenting as a continuous phenotype, the ability to accurately determine intermediate phenotypes is critical in understanding ART resistance and identifying contributing genotypes beyond
kelch13 propeller mutations. The efficiency of the eRRSA makes it an excellent replacement for the traditional RSA in any study of ART resistance requiring accuracy and higher throughput. The 15 cloned parasites examined include three which lack
kelch13 mutations but show PC
1/2 > 5. These include one clone (NHP4373) with PC
1/2 = 7.1. Interestingly, these clones also show high eRRSA values, confirming their ART resistant status. These results provide further support that ART resistance may result from mutations elsewhere in the parasite genome, or perhaps from non-coding regulatory changes controlling
kelch13 activity [
17].
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.